Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
28 8월 2009 - 9:00PM
PR Newswire (US)
BEIJING, Aug. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
(NYSE:SVA), a leading provider of biopharmaceutical products in
China, announced today that the Beijing Public Health Bureau has
selected Sinovac as one of the four manufacturers to supply
Anflu(R), Sinovac's seasonal influenza vaccine, for the benefit of
the citizens of Beijing. The Beijing Public Health Bureau completed
the bidding process for the purchase of flu vaccines and
corresponding services for 2009 on August 26, 2009. The agreement
will be executed after the public notice period. In order to
prevent and control infectious disease and to avoid contracting
both the seasonal flu virus and the H1N1 virus, 2.8 million Beijing
citizens will receive free inoculations against the seasonal
influenza. Under the Bureau's plan, people over the age of 60, as
well as elementary and secondary school students, will be
inoculated with the influenza vaccine at no charge. Previously,
school students were inoculated with the influenza vaccine at a
charge of 20 RMB per person with allowances from the Bureau. Mr.
Weidong Yin, Chairman, President and CEO of Sinovac, commented, "As
part of our mission to develop vaccines to combat the spread of
disease in China and around the world, we are pleased to again be
among the seasonal flu suppliers to the Beijing government. We are
confident of our flexibility to be able to fill large seasonal flu
vaccine orders while also executing the R&D and large-scale
production of our H1N1 vaccine. Our ability to produce multiple
sophisticated and high-quality vaccines simultaneously is further
proof that Sinovac is a leading vaccine provider." Developed and
manufactured by Sinovac, Anflu is the only split influenza vaccine
produced in China without preservatives. Over the past two years,
the Company has expanded its manufacturing capacity for seasonal
influenza vaccine to five million doses per year, and the same
production line can produce 20 million doses of pandemic influenza
vaccine, using a grant from China's National Development and Reform
Commission. In other news, Sinovac recently reported top-line
preliminary results of H1N1 vaccine clinical trials. The results
show the H1N1 vaccine developed by Sinovac is quite safe and has a
good immunogenicity profile. About Sinovac Sinovac Biotech Ltd. is
a China-based biopharmaceutical company that focuses on the
research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's
vaccine products include Healive(R) (hepatitis A), Bilive(R)
(combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM),
Sinovac's pandemic influenza vaccine (H5N1), has already been
approved for government stockpiling. Sinovac is developing vaccines
for enterovirus 71, universal pandemic influenza, Japanese
encephalitis, and human rabies. Its wholly owned subsidiary,
Tangshan Yian, is conducting field trials for independently
developed inactivated animal rabies vaccines. Safe Harbor Statement
This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar statements. Among
other things, the business outlook and quotations from management
in this press release contain forward-looking statements.
Statements that are not historical facts, including statements
about Sinovac's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and
uncertainties. A number of important factors could cause actual
results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any
obligation to update any forward-looking statement, except as
required under applicable law. For more information, please
contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088
x9871 Fax: +86-10-6296-6910 Email: Investors: Amy Glynn/Sara
Pellegrino The Ruth Group Tel: +1-646-536-7023/7002 Email: or
Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email:
DATASOURCE: Sinovac Biotech Ltd. CONTACT: Helen G. Yang of Sinovac
Biotech Ltd., +86-10-8289-0088 x9871, Fax +86-10-6296-6910, ; or
Investors, Amy Glynn & Sara Pellegrino, +1-646-536-7023/7002, ,
, or Media, Janine McCargo, +1-656-536-7033, all of The Ruth Group
Copyright